{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Part+1&page=3",
    "query": {
      "condition": "Part 1",
      "page": 3
    },
    "page_size": 10
  },
  "pagination": {
    "page": 3,
    "page_size": 10,
    "total_count": 403,
    "total_pages": 41,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Part+1&page=4&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Part+1&page=2&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-22T13:59:11.366Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00478634",
      "title": "A Phase 1 Study Investigating the Combination of RAD001, Cetuximab and Irinotecan as Second-line Therapy After FOLFOX (or XELOX) Plus Bevacizumab in Patients With Metastatic Colorectal Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Colorectal Cancer",
        "Colorectal Carcinoma",
        "Colorectal Tumors",
        "Neoplasms, Colorectal"
      ],
      "interventions": [
        {
          "name": "RAD001, Cetuximab, Irinotecan",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 19,
      "start_date": "2007-05",
      "completion_date": "2009-09",
      "has_results": false,
      "last_update_posted_date": "2012-11-02",
      "last_synced_at": "2026-10-22T13:59:11.366Z",
      "location_count": 16,
      "location_summary": "Fayetteville, Arkansas • Bakersfield, California • La Jolla, California + 13 more",
      "locations": [
        {
          "city": "Fayetteville",
          "state": "Arkansas"
        },
        {
          "city": "Bakersfield",
          "state": "California"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Northridge",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00478634"
    },
    {
      "nct_id": "NCT04147715",
      "title": "Evaluation of Safety, Tolerability, Pharmacokinetics, Drug-Drug and Food Interactions of Single and Multiple Doses of S-648414 in Healthy Adults",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy Volunteer"
      ],
      "interventions": [
        {
          "name": "S-648414",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Midazolam",
          "type": "DRUG"
        },
        {
          "name": "Dolutegravir",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Shionogi",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 98,
      "start_date": "2019-10-09",
      "completion_date": "2020-09-29",
      "has_results": true,
      "last_update_posted_date": "2021-11-01",
      "last_synced_at": "2026-10-22T13:59:11.366Z",
      "location_count": 1,
      "location_summary": "Austin, Texas",
      "locations": [
        {
          "city": "Austin",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04147715"
    },
    {
      "nct_id": "NCT07170189",
      "title": "Phase 1, Open-Label, Randomized, Study of the Safety and Pharmacokinetics of HU6",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Overweight"
      ],
      "interventions": [
        {
          "name": "HU6",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Rivus Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 59,
      "start_date": "2025-10-13",
      "completion_date": "2025-12-04",
      "has_results": false,
      "last_update_posted_date": "2026-01-21",
      "last_synced_at": "2026-10-22T13:59:11.366Z",
      "location_count": 1,
      "location_summary": "Minneapolis, Minnesota",
      "locations": [
        {
          "city": "Minneapolis",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07170189"
    },
    {
      "nct_id": "NCT02653391",
      "title": "A Study Investigating the Safety, Tolerability, and Efficacy of Elamipretide Topical Ophthalmic Solution for the Treatment of Fuchs' Corneal Endothelial Dystrophy (FCED)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Fuchs' Corneal Endothelial Dystrophy (FCED)"
      ],
      "interventions": [
        {
          "name": "Part A Elamipretide 1.0% Ophthalmic Solution",
          "type": "DRUG"
        },
        {
          "name": "Part B Elamipretide 3.0% Ophthalmic Solution",
          "type": "DRUG"
        },
        {
          "name": "Part A Placebo",
          "type": "DRUG"
        },
        {
          "name": "Part B Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Stealth BioTherapeutics Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 22,
      "start_date": "2016-02",
      "completion_date": "2018-12",
      "has_results": true,
      "last_update_posted_date": "2021-09-17",
      "last_synced_at": "2026-10-22T13:59:11.366Z",
      "location_count": 2,
      "location_summary": "Edgewood, Kentucky • Boston, Massachusetts",
      "locations": [
        {
          "city": "Edgewood",
          "state": "Kentucky"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02653391"
    },
    {
      "nct_id": "NCT02851459",
      "title": "Tailoring of Vaccine-Focused Messages: Moral Foundations",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Childhood Vaccinations"
      ],
      "interventions": [
        {
          "name": "Baseline Survey",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Pre-intervention Survey",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Morally Congruent Message",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Morally Non-Congruent Message",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Control Message",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Post-Intervention Survey",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL"
      ],
      "sponsor": "Emory University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "18 Years to 50 Years"
      },
      "enrollment_count": 850,
      "start_date": "2016-08",
      "completion_date": "2016-10",
      "has_results": false,
      "last_update_posted_date": "2017-03-10",
      "last_synced_at": "2026-10-22T13:59:11.366Z",
      "location_count": 1,
      "location_summary": "Atlanta, Georgia",
      "locations": [
        {
          "city": "Atlanta",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02851459"
    },
    {
      "nct_id": "NCT02235740",
      "title": "A Study Conducted in Subjects With Relapsed/Refractory Multiple Myeloma (MM); to Determine Dose of Afuresertib in Combination With Carfilzomib (Part 1) and to Investigate the Safety, Pharmacokinetic and Clinical Activity of the Combination Compared With Carfilzomib Alone (Part 2)",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Cancer"
      ],
      "interventions": [
        {
          "name": "Afuresertib",
          "type": "DRUG"
        },
        {
          "name": "Carfilzomib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novartis",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 1,
      "start_date": "2014-11",
      "completion_date": "2015-10",
      "has_results": false,
      "last_update_posted_date": "2016-05-04",
      "last_synced_at": "2026-10-22T13:59:11.366Z",
      "location_count": 1,
      "location_summary": "Cary, North Carolina",
      "locations": [
        {
          "city": "Cary",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02235740"
    },
    {
      "nct_id": "NCT00214279",
      "title": "MMF Monotherapy and Immune Regulation in Kidney Transplant Recipients: Part 1 Steroid Withdrawal",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Renal Transplantation"
      ],
      "interventions": [
        {
          "name": "Corticosteroid withdrawal",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Wisconsin, Madison",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "55 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "55 Years and older"
      },
      "enrollment_count": 32,
      "start_date": "2002-05",
      "completion_date": "2007-11",
      "has_results": false,
      "last_update_posted_date": "2012-06-26",
      "last_synced_at": "2026-10-22T13:59:11.366Z",
      "location_count": 1,
      "location_summary": "Madison, Wisconsin",
      "locations": [
        {
          "city": "Madison",
          "state": "Wisconsin"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00214279"
    },
    {
      "nct_id": "NCT04285827",
      "title": "Safety of Single Doses of CSL889 in Adult Patients With Sickle Cell Disease",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Sickle Cell Disease"
      ],
      "interventions": [
        {
          "name": "CSL889",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "CSL Behring",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "60 Years",
        "sex": "ALL",
        "summary": "18 Years to 60 Years"
      },
      "enrollment_count": 28,
      "start_date": "2021-05-20",
      "completion_date": "2023-07-24",
      "has_results": false,
      "last_update_posted_date": "2023-09-06",
      "last_synced_at": "2026-10-22T13:59:11.366Z",
      "location_count": 8,
      "location_summary": "Chicago, Illinois • Baltimore, Maryland • Minneapolis, Minnesota + 5 more",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Minneapolis",
          "state": "Minnesota"
        },
        {
          "city": "The Bronx",
          "state": "New York"
        },
        {
          "city": "Greenville",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04285827"
    },
    {
      "nct_id": "NCT04460703",
      "title": "COVID-19 Vaccine Messaging, Part 1",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Vaccination",
        "COVID-19"
      ],
      "interventions": [
        {
          "name": "Control message",
          "type": "OTHER"
        },
        {
          "name": "Baseline message",
          "type": "OTHER"
        },
        {
          "name": "Personal freedom message",
          "type": "OTHER"
        },
        {
          "name": "Economic freedom message",
          "type": "OTHER"
        },
        {
          "name": "Self-interest message",
          "type": "OTHER"
        },
        {
          "name": "Community interest message",
          "type": "OTHER"
        },
        {
          "name": "Economic benefit message",
          "type": "OTHER"
        },
        {
          "name": "Guilt message",
          "type": "OTHER"
        },
        {
          "name": "Embarrassment message",
          "type": "OTHER"
        },
        {
          "name": "Anger message",
          "type": "OTHER"
        },
        {
          "name": "Trust in science message",
          "type": "OTHER"
        },
        {
          "name": "Not bravery message",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "Yale University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 4000,
      "start_date": "2020-07-03",
      "completion_date": "2020-07-08",
      "has_results": false,
      "last_update_posted_date": "2022-05-05",
      "last_synced_at": "2026-10-22T13:59:11.366Z",
      "location_count": 1,
      "location_summary": "New Haven, Connecticut",
      "locations": [
        {
          "city": "New Haven",
          "state": "Connecticut"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04460703"
    },
    {
      "nct_id": "NCT02374047",
      "title": "A 2-Part, Phase 1, Single and Multiple Ascending Dose Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of CAT-2054 in Healthy Subjects",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Hypercholesterolemia"
      ],
      "interventions": [
        {
          "name": "CAT-2054",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "CAT-2054-C",
          "type": "DRUG"
        },
        {
          "name": "Atorvastatin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Catabasis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 118,
      "start_date": "2015-01",
      "completion_date": "2015-07",
      "has_results": false,
      "last_update_posted_date": "2021-01-28",
      "last_synced_at": "2026-10-22T13:59:11.366Z",
      "location_count": 1,
      "location_summary": "West Bend, Wisconsin",
      "locations": [
        {
          "city": "West Bend",
          "state": "Wisconsin"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02374047"
    }
  ]
}